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Summary
 
The nonclassical MHC class I molecule human histocompatibility leukocyte antigen (HLA)-G
is selectively expressed on fetal trophoblast tissue at the maternal–fetal interface in pregnancy. It
has long been suggested that HLA-G may inhibit maternal natural killer (NK) cells through in-
teraction with particular NK cell receptors (KIRs). To investigate interactions of HLA-G, we con-
structed phycoerythrin-labeled tetrameric complexes of HLA-G refolded with a self-peptide.
These HLA-G tetramers failed to bind to NK cells and cells transfected with CD94/NKG2 and
killer immunoglobulin-like NK receptors. In contrast, HLA-G tetramers did bind to peripheral
blood monocytes, staining a CD16
 
1
 
CD14
 
mid
 
 subset with greater intensity. On transfectants,
HLA-G tetramers bound to inhibitory immunoglobulin-like transcript (ILT)2 and ILT4 recep-
tors. However, staining in the presence of antibodies reactive with ILT receptors revealed that
the interaction of HLA-G tetramers with blood monocytes was largely due to binding to ILT4.
These results suggest that the primary role of HLA-G may be the modulation of myelomono-
cytic cell behavior in pregnancy.
Key words: immunoglobulin-like transcript • monocyte • natural killer cell • CD94 • killer 
immunoglobulin-like receptor
 
T
 
he MHC class Ib molecule HLA-G has been the sub-
ject of considerable interest for several years because of
its unique tissue distribution. HLA-G is expressed primarily
by a population of fetal extravillous cytotrophoblast cells
that lie in direct contact with maternal uterine mucosa dur-
ing pregnancy (1–3). Because of this location, many have
speculated that HLA-G may act to modulate the maternal
immune response towards the semiallogeneic fetus.
Fetal trophoblast tissue largely fails to express MHC class I
HLA-A and -B or MHC class II molecules (4), perhaps es-
caping T cell–mediated recognition. However, many mater-
nal NK cells cluster adjacent to trophoblast tissue (5), and it
has often been proposed that HLA-G expression might be re-
sponsible for their inhibition. Indeed, several groups have
provided functional evidence that transfection of HLA-G
could inhibit NK cells expressing CD94/NKG2A/B NK
cell receptors, implying that HLA-G was directly recognized
(6–8). However, these results must now be reexamined in
light of recent discoveries that nonclassical HLA-E is the
ligand for CD94/NKG2A/B/C receptors and cell surface ex-
pression of HLA-E is upregulated upon acquisition of peptides
derived from the leader sequences of other MHC class I mole-
cules, including HLA-G (9–14). HLA-G has also been sug-
gested to interact with NK cell receptors of the killer Ig-like
receptor (KIR)
 
1
 
 family, including KIR2DL1, KIR2DL3,
and KIR3DL1 (15, 16), with known specificities for two
groups of HLA-C and HLA-Bw4 molecules, respectively.
KIR2DL4 (or p49, KIR103) has also been reported to recog-
nize several MHC class I molecules including HLA-G (17).
Maternal T cells and macrophages are also present in appre-
ciable numbers at the maternal–fetal tissue interface, suggesting
other possible interactions for HLA-G. Indeed, another group
of Ig superfamily receptors known as ILTs (Ig-like transcripts)
(18–22), LIRs (leukocyte Ig-like receptors) (23–25), or
MIRs (monocyte/macrophage Ig-like receptors) (26, 27)
are expressed in many cell subsets, particularly myelomono-
cytic cells. Fusion proteins of certain members of this family
 
1
 
Abbreviations used in this paper:
 
 DC, dendritic cell; Tet, tetramer; ILT, im-
munoglobulin-like transcript; KIR, killer immunoglobulin-like receptor. 
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have been shown to bind to several MHC class I molecules
including HLA-G on transfectants (19, 20, 25).
To investigate whether HLA-G was capable of interaction
with such a diversity of receptors and to identify new ligands,
we created HLA-G tetrameric complexes. Recombinant
HLA-G was refolded in vitro with 
 
b
 
2 microglobulin and
a synthetic self-peptide, and conjugated with PE-labeled
ExtrAvidin (Sigma Chemical Co.) molecules to create tetrameric
complexes. Similar MHC class I tetramers have proven to be
very powerful tools allowing visualization of interactions with
TCRs and NK cell receptors in flow cytometric analyses (28).
 
Materials and Methods
 
Antibodies.
 
42D1 mAb (rat IgG2a) has been described previ-
ously (20) and 27D6 mAb (rat IgM) was another clone obtained
from the same fusion. TC16-28C8 and TC16-40H2 mAbs (both
rat IgG1) were produced by immunizing female Lewis rats with a
human Fc
 
g
 
1 fusion protein of ILT6, a receptor that naturally
lacks a transmembrane domain.
Reactivities of 40H2, 28C8, 42D1, and 27D6 are detailed in
the legend to Fig. 5, based on flow cytometry experiments using
the panel of cell surface ILT receptor transfectants available for
this study (as shown in Fig. 4).
 
Cells.
 
Baf3 cells transfected with CD94/NKG2A (29), CD94/
NKG2C/DAP12 (29), or KIR receptors (30); Jurkat cells trans-
fected with ILT3 (21); RBL cells transfected with ILT4 or ILT5
(20); and P815 cells transfected with ILT1 (22) have been de-
scribed previously. Baf3 cells transfected with ILT2 were generated
as previously described (29). RBL cells transfected with ILT8, an
activating receptor similar to ILT1, were produced as previously
described (20).
 
HLA-G Tetramers.
 
Using HLA-G*01012 cDNA (1) as a
template, extracellular domains (amino acids 1–276) of HLA-G1
were amplified by PCR using primers: 5
 
9
 
-ctcgagcatatgggTtc-
TcaTtcTatgCgTtatttTagcgcAgcAgtTtcTcgTccAggccgcggg-3
 
9 
 
and
5
 
9
 
-atgcagggatccctgcttccatctcagcatgagggg-3
 
9
 
 and cloned into a
pGMT7 vector derivative containing a BirA recognition and bio-
tinylation site in frame at the COOH-terminus (11). The NH
 
2
 
-
terminal primer contained several synonymous nucleotide substi-
tutions (capitalized) designed to optimize protein expression from
 
Escherichia coli
 
 strain BL21 pLysS. HLA-G tetramers were created
essentially as previously described (11), using synthetic peptide
RIIPRHLQL (or KIPAQFYIL where indicated) (Genosys) pre-
viously shown to interact with HLA-G (31, 32). Dilutions for
flow cytometry staining contained 
 
z
 
14 
 
m
 
g/ml of refolded HLA-
G/
 
b
 
2 microglobulin.
HLA-E*0101 and HLA-B*2705 tetramers were refolded with
peptides VMAPRTLFL and KRWIILGLNK, respectively (11, 33).
 
Flow Cytometry.
 
Staining of PBMCs and transfectants was per-
formed using standard protocols. For PBMCs, PBS 0.05% NaN
 
3
 
buffer was supplemented with 10% human serum for blocking and
primary incubation, and 1–2% human serum for washes and sec-
ondary incubations. PBMCs were stained on ice immediately af-
ter Ficoll-Hypaque separation or frozen and thawed immediately
before use. Cells were analyzed on a FACScan™.
 
Results and Discussion
 
HLA-G Tetramers Bind to Myelomonocytic Cells from Periph-
eral Blood.
 
We constructed HLA-G tetrameric complexes
 
refolded with a synthetic self-peptide (RIIPRHLQL) derived
from human histone H2A (31, 32). These PE-labeled HLA-G
tetramers were used to stain PBMCs from healthy individ-
uals. No significant HLA-G tetramer binding was observed
on CD56
 
1
 
 NK cells, CD3
 
1
 
 T cells, or CD19
 
1
 
 B cells within
the gated lymphocyte population (Fig. 1). In contrast, when
an electronic gate was set on myelomonocytic cells, signifi-
cant HLA-G tetramer interaction was observed. CD14
 
high
 
cells, representing the majority of monocytes, stained weakly,
with intensity of staining varying between individuals (Fig. 1
and data not shown). In addition, a subset of cells within the
myelomonocytic population exhibited considerably brighter
HLA-G tetramer staining (Fig. 1). These cells ranged from
CD14
 
high
 
 to CD14
 
2
 
. In freshly isolated PBMCs from six
individuals, this HLA-G Tet
 
bright
 
 subset represented 5–12%
of cells within the myelomonocytic gate, or 1–2.8% of total
PBMCs. Almost indistinguishable patterns of staining were
obtained with an HLA-G tetramer refolded with a second
peptide (KIPAQFYIL) (data not shown) also known to bind
to HLA-G (31). However, interactions with myelomono-
cytic cells were not unique to HLA-G, as tetramers of other
MHC class I molecules (including HLA-A*0201, HLA-A*
6802, HLA-B*3501, and HLA-E*0101) exhibited similar
staining, although often with considerably less intensity (data
not shown).
 
HLA-G Tetramers Brightly Stain a Distinct CD16
 
1
 
CD14
 
mid
 
Monocyte Subset.
 
To further characterize the cells staining
intensely with HLA-G tetramers, the expression of a num-
ber of other cell surface markers was examined in three
individuals. Levels of CD13, CD32 (Fc
 
g
 
RII), and CD33
on HLA-G Tet
 
bright
 
 cells were comparable or slightly lower
than most monocytes (Fig. 2). The expression of CD33
and CD13 on the HLA-G Tet
 
bright
 
 subset was consistent
with these cells having a myeloid origin. The HLA-G
Tet
 
bright
 
 cells appeared to form a distinct subgroup, express-
ing much higher CD16 (Fc
 
g
 
RIII), lower CD64 (Fc
 
g
 
RI),
lower CD11b, higher CD11c, higher CD45RA, and
slightly lower CD45RO levels than the majority of mono-
cytes (Fig. 2). Similarly, HLA-G Tet
 
bright
 
 cells showed
slightly higher levels of costimulatory CD86 (B7-2) and
CD40 molecules and MHC class II (anti–HLA-DR or
anti–pan-class II) compared with typical monocytes (Fig. 2
and data not shown). This phenotype is very similar to a
previously described CD16
 
1
 
CD14
 
mid
 
 monocyte subset
(34). Ziegler-Heitbrock has suggested that these CD16
 
1
 
CD14
 
mid
 
 cells may be differentiating to become tissue mac-
rophages (34). Intracellular staining for CD68, which is
highly expressed by macrophages, did reveal a marginally
brighter signal in HLA-G Tet
 
bright
 
 cells (data not shown).
However, the HLA-G Tet
 
bright
 
 subset failed to stain with
antibodies to scavenger receptor A or mannose receptor
found on tissue macrophages (data not shown). Many of
these patterns of marker expression are also suggestive of a
peripheral blood dendritic cell (DC) phenotype (35–37).
Expression of CD16, however, is inconsistent with prior
descriptions of blood DCs (35–37). HLA-G Tet
 
bright
 
 cells
also fail to express DC-associated markers CD1a and CD83
(data not shown). Nonetheless, the HLA-G Tet
 
bright
 
 subset 
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could represent a stage in either the macrophage or DC
differentiation pathways.
 
HLA-G Tetramers Bind to ILT2 and ILT4 Receptors.
 
To
search for the receptors responsible for the observed stain-
ing of PBMCs, we stained a number of transfectants with
HLA-G tetramers. We began with cells transfected with
several NK cell receptors previously suggested to interact
with HLA-G (6–8, 15, 16). As shown in Fig. 3 A, HLA-G
tetramers did not bind to transfectants expressing high lev-
els of CD94/NKG2A or CD94/NKG2C/DAP12. Similarly,
we did not observe any binding of HLA-G tetramers to
cells transfected with KIR2DL1, KIR2DL3, KIR3DL1,
KIR3DL2, or KIR2DL4 members of the KIR family (Fig.
3 B). These findings correlate with the failure of HLA-G
tetramers to stain NK cells from peripheral blood. It re-
mains possible that interactions might be missed if they
were of low affinity or peptide dependent, or required glyco-
sylation unattained on HLA-G expressed in 
 
E
 
.
 
 coli
 
.
 
 
 
How-
ever, the efficient interactions of similarly constructed
HLA-E tetramers with CD94/NKG2A and C receptors
and HLA-B*2705 tetramers with KIR3DL1 (Fig. 3) con-
siderably weaken such arguments. In addition, the previ-
ously reported recognition of HLA-G by NK clones ex-
pressing CD94/NKG2 receptors (6–8) can be explained by
interactions with HLA-E, which is upregulated upon ac-
quisition of leader sequence peptides from HLA-G (9–14).
We next investigated HLA-G tetramer interactions with
receptors of the ILT (or LIR or MIR) family (18–27).
HLA-G tetramers efficiently stained transfectants express-
ing ILT4 and ILT2 receptors (Fig. 4). HLA-G tetramer
binding, however, was quite dependent upon the density
of receptor. Significantly higher expression of ILT2 was
necessary to observe efficient HLA-G tetramer binding,
suggesting that this interaction may have relatively lower
affinity compared with ILT4 (Fig. 4 and data not shown).
However, such interactions were not unique to HLA-G, as
Figure 1. HLA-G tetramers
bind to peripheral blood my-
elomonocytic cells. PBMCs
from a healthy individual were
stained with PE-labeled HLA-G
tetramers or ExtrAvidin-PE con-
trol and anti-CD3, -CD56,
-CD19, or -CD14 directly la-
beled mAb. An electronic gate
based on forward and side light
scatter properties was set on lym-
phoid cells (A) or myelomono-
cytic cells (B). Patterns in A were
not significantly different from
ExtrAvidin-PE control.
Figure 2. HLA-G tetramers
intensely stain a distinct CD161
CD14mid monocyte subset. PBMCs
from a healthy individual were
stained with PE-labeled HLA-G
tetramers and several FITC-
labeled or unconjugated mAbs as
indicated. Only cells within a my-
elomonocytic light scatter gate are
shown. Results with FITC-
labeled or unconjugated IgG1 and
IgG2a control mAbs were very
similar to unlabeled IgG1 shown.
Unlabeled mAbs were detected
with FITC-conjugated F(ab9)2
goat anti–mouse Ig. Additionally,
an HLA-G tetramer created with
a different peptide (KIPAQFYIL)
displayed a very similar pattern of
staining (data not shown). 
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tetrameric complexes of several other MHC class I mole-
cules (including HLA-A*0201, A*6802, B*3501, B*2705,
and HLA-E*0101) also stained the ILT2 and ILT4 transfec-
tants (data not shown and reference 20). Binding of certain
molecules, such as HLA-E, appeared less efficient. These
results are consistent with the findings that fusion proteins
of ILT2 and ILT4 could interact with cells transfected with
certain MHC class I molecules including HLA-G (19, 20, 25).
HLA-G tetramers did not bind to cells transfected with
ILT1, ILT3, ILT5, or ILT8 (Fig. 4), confirming previous
reports that failed to observe interactions of fusion proteins
with MHC class I molecules (20, 21, 24).
 
HLA-G Tetramer Staining of Monocytes Is Predominately
Due to Interaction with ILT4.
 
To determine if the HLA-G
tetramer staining of blood monocytes was the result of in-
teraction with these ILT receptors, we stained PBMCs
with HLA-G tetramers in the presence of ILT-reactive
mAbs. The addition of 40H2 mAb, recognizing several
members of the ILT family, caused an enhancement of
HLA-G tetramer binding to both CD14
 
high
 
 and CD14
 
mid
 
monocyte subsets, providing direct evidence for the in-
volvement of ILT receptors (Fig. 5). Bivalent 40H2 rat
IgG1 probably cross-linked receptors thus facilitating for-
mation of multivalent tetramer interactions. 28C8 mAb,
which reacted only with ILT2 and ILT4 of the panel of cell
surface ILT receptors available for the study (shown in Fig. 4),
almost completely blocked HLA-G tetramer binding to
monocytes (Fig. 5). Thus, the interactions responsible for
monocyte staining were narrowed to ILT2 and ILT4, con-
sistent with the staining on transfectants, although binding
to other receptors sharing very similar antigenic determi-
nants could not be completely excluded. Further experi-
ments with 42D1 and 27D6 mAbs, which recognize ILT4
but not ILT2, revealed that the majority of HLA-G tetra-
mer staining of monocytes was the result of binding to
ILT4. 42D1 mAb enhanced HLA-G tetramer staining of
monocytes (Fig. 5) and 27D6 mAb
 
 
 
almost completely ab-
rogated HLA-G tetramer binding (Fig. 5). These results are
consistent with the absence of HLA-G tetramer staining on
Figure 3. HLA-G tetramers do not bind to NK receptors. Baf3 cells
transfected (A) with CD94 and NKG2A or CD94, NKG2C, and DAP12,
or (B) with several KIR receptors were stained with HLA-G, HLA-E*0101,
or HLA-B*2705 tetramers, or ExtrAvidin-PE or Streptavidin-PE controls.
Expression of transgenes was verified with mAbs recognizing CD94, KIRs,
or the FLAG peptide epitope, as indicated.
Figure 4. HLA-G tetramers bind to ILT2 and
ILT4. HLA-G tetramers or ExtrAvidin-PE control
were used to stain P815 cells transfected with ILT1;
Baf3 cells transfected with ILT2; Jurkat cells trans-
fected with ILT3; or RBL cells transfected with
ILT4, ILT5, or ILT8. Expression was verified with
ILT-reactive or anti-FLAG mAbs as shown. 
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peripheral blood B cells, T cells, and NK cells that express
some ILT2 (19, 25). Indeed, the pattern of tetramer stain-
ing matches the restricted expression of ILT4 on myelo-
monocytic cells (20, 25). In two-color flow cytometry
analyses, HLA-G tetramer binding correlated with ILT4
staining (42D1) (data not shown) and CD16
 
1
 
 and CD14
 
mid
 
monocytes exhibited higher expression of ILT4 compared
with typical CD14
 
high
 
CD16
 
2
 
 monocytes (data not shown
and reference 25). If HLA-G Tet
 
bright
 
 cells are indeed dif-
ferentiating to become macrophages (34) or DCs, ILT4
expression may be modulated in preparation for the tis-
sue phenotype. Alternatively, ligation or lack of ligation of
ILT4 may be involved in the control of these differentia-
tion pathways.
In conclusion, in this study we demonstrate an inter-
action of HLA-G tetrameric complexes with peripheral
blood monocytes that results from binding to ILT4 recep-
tors. We failed to observe any evidence of interaction of
HLA-G tetramers with CD94/NKG2 or KIR NK cell re-
ceptors. This suggests that a dominant role of HLA-G may
be the modulation of monocyte, macrophage, or DC be-
havior in pregnancy. ILT4 possesses inhibitory ITIM mo-
tifs in its cytoplasmic domain, and its ligation can inhibit
Ca
 
2
 
1
 
 fluxes and tyrosine phosphorylation events in myelo-
monocytic cells in response to several stimulatory signals
(20, 25). Thus, HLA-G may provide important inhibitory
signals capable of modulating antigen presentation, phago-
cytosis, antibody-dependent cell-mediated cytotoxicity, or
cytokine production by the numerous maternal macro-
phages present at the maternal–fetal tissue interface.
Interactions with ILT4 are not unique to HLA-G, how-
ever, as tetramers of several classical MHC class I molecules
and HLA-E also bound to monocytes and transfectants, al-
though in some cases with considerably lower efficiency.
Fetal trophoblasts are deficient in HLA-A and -B classical
MHC class I expression (4). Thus, it is possible that expres-
sion of HLA-G on this tissue only replaces the inhibitory
signals to macrophages normally provided by classical class I
molecules in other tissues in the body.
Although the pattern of HLA-G tetramer staining of
PBMCs closely mirrored the restricted expression of ILT4
on myelomonocytic cells (20, 25), HLA-G tetramers were
also able to stain transfected cells expressing very high levels
of ILT2 inhibitory receptors. However, transfectants with
lower ILT2 expression did not efficiently bind HLA-G tet-
ramers (data not shown). Thus, the failure of HLA-G tet-
ramers to stain B, T, and NK cells, which express some
ILT2 (19, 25), likely reflects a relatively lower binding
affinity compared with ILT4. However, interactions of
HLA-G with ILT2 receptors may allow functional inhibi-
tion of many cell subsets (19).
Finally, we can not rule out that HLA-G also serves as a
restriction element for maternal T cells, because HLA-G
tetramers refolded with self-peptides would not be ex-
pected to interact with antigen-specific T cell receptors.
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